Philips Invests in Chengyi Jiaren, Partners with Meinian Dajiankang to Launch Integrated Sleep and Respiratory Chronic Disease Management Platform

VCBeat (WeChat ID: vcbeat) has learned, December 21, Philips (China) Investment Co., Ltd. (hereinafter referred to as “"Philips") announced a partnership with Chengyi Jiaren Technology (Tianjin) Co., Ltd. (hereinafter referred to as“Orange Family””) officially signed a strategic business cooperation agreement with Meinian Onehealth Healthcare Industrial (Group) Co., Ltd. (hereinafter referred to as “"Meinian Onehealth"），In the field of chronic respiratory disease management, we provide a "one-stop comprehensive disease management solution" covering initial screening, referral, treatment, and rehabilitation.

To strengthen the partnership between the two parties, Philips also announced a capital investment and equity stake in Chengyi Jiaren. The signing ceremony was held at the Philips Greater China headquarters. Attendees included Mr. He Guowei, CEO of Philips Greater China; Mr. Yu Rong, Chairman of Meinian Onehealth Healthcare; and Ms. Zhang Dan, President of Chengyi Jiaren.

Group Photo of Senior Executives from Orange Family, Philips, and Meinian Onehealth

As a company focused on the “Health Tech” sector, Philips is committed to integrating advanced digital and artificial intelligence technologies with extensive clinical expertise and consumer insights. It strives to launch integrated innovative solutions across the entire “healthcare continuum”—spanning healthy lifestyles, disease prevention, diagnosis, treatment, and home care—to enhance people’s health and improve healthcare outcomes.

“Respiratory Care” is one of the four key health areas prioritized by Philips.As a global leader in respiratory care, Philips offers not only intelligent air purifiers, home and medical non-invasive ventilators, ventilator masks, portable oxygen concentrators, nebulizers, and medication delivery devices throughout the “continuum of health care,” but also provides an integrated sleep solution for patients with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and a “Lung Care Manager” home care solution for patients with Chronic Obstructive Pulmonary Disease (COPD).

Orange FamilyEstablished in 2014, is a service provider specializing in the management of chronic respiratory diseases, establishing an integrated management system encompassing initial screening, referral, treatment, and rehabilitation for respiratory conditions.In addition to owning portable wearable medical devices such as the “Chengyi Pulse Oximeter” and the “Remote Portable Spirometer,” it has established a “Chronic Respiratory Disease Diagnosis and Treatment Management System” on its domestically pioneered cloud-based doctor-patient interaction platforms, “Chengyi Health” and “Chengyi Doctor.”

Meinian Onehealth is China's largest health checkup and medical services group., a constituent of the CSI 300 Index, ranks first in market capitalization among listed companies in the health services sector. It owns professional health examination and medical brands such as “Meinian Onehealth,” “Ciming,” “Ciming Aoya,” and “Meizhao.” Currently, it operates nearly 400 medical and health examination centers in over 200 core cities across China, making it the world’s largest preventive medicine platform and entry point for health services. In 2017, Meinian Health provided professional health services to nearly 20 million people, with projections to serve over 100 million people by 2021.

In 2016, Chengyi Jiaren entered into a strategic partnership with Meinian Onehealth, establishing Sleep Centers and Respiratory Chronic Disease Management Centers across more than 80 of its health examination facilities., introduced multiple products to enrich Meinian’s one-stop health checkup services. By leveraging health screenings as an entry point, it accurately identifies patients and high-risk populations testing positive for obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD), and provides corresponding solutions for those who test positive.

Severe snoring, medically known as"Obstructive Sleep Apnea”, is a serious threat to health. Recurrent intermittent hypoxia during sleep significantly increases the risk of hypertension, cardiovascular and cerebrovascular diseases, diabetes, and other conditions, and is associated with Alzheimer’s disease, arrhythmias, and other chronic respiratory disorders. Moreover, due to repeated sleep disruptions, patients remain in a state of fragmented and light sleep for prolonged periods, leading to daytime somnolence, poor concentration, and memory impairment. Sleep-disordered breathing imposes a substantial social and health-economic burden.

Data from abroad shows that the annual medical costs related to sleep disorders in the United States reach $3.4 billion, while the indirect economic losses due to reduced productivity and traffic accidents amount to approximately $15.9 billion per year.Therefore, timely and effective diagnosis and treatment of such conditions can significantly reduce the risk of developing chronic diseases, including cardiovascular and cerebrovascular disorders.

In China, the prevalence of sleep-disordered breathing is as high as 5%, yet fewer than 1% of patients receive treatment.Such patients not only require timely diagnosis and treatment at specialized medical institutions but also need self-health management capabilities to prevent and alleviate disease symptoms. Therefore, the sleep and respiratory management market not only holds significant opportunities but also carries profound implications for the prevention and control of chronic diseases in Chinese society.

Philips offers a globally leading integrated solution for Obstructive Sleep Apnea (OSA).Philips’ latest integrated smart sleep health solution, DreamFamily, is set to launch in the Chinese market in early 2018., delivering respiratory therapy experiences and sleep health solutions tailored to the usage habits and individual characteristics of Chinese users, along with seamless care enabled by real-time connectivity between patients and healthcare providers.

Philips and Chengyi Jiaren Hold Signing Ceremony

Based on insights into the importance of this disease and its market potential, in order to better serve the Chinese market,Philips Deepens Strategic Collaboration with Chengyi Jiaren, in partnership with Meinian Onehealth, leverages Philips’ globally leading diagnostic and therapeutic solutions for sleep-disordered breathing to establish a closed-loop management pathway for obstructive sleep apnea (OSA)—spanning initial screening, diagnosis, referral, treatment, rehabilitation, and self-health management—thereby providing patients with this chronic condition with a truly “one-stop comprehensive disease management solution.”

Under the agreement, the three parties will also leverage Philips’ strengths in innovative solutions, Meinian’s industrial chain advantages in the general health sector, and Chengyi Jiaren’s mature and professional service operation experience to extend their reach into out-of-hospital and home care for other chronic respiratory diseases, thereby comprehensively establishing a personal health management ecosystem.

Mr. He Guowei, CEO of Philips Greater China, stated: “Starting with ‘health checkups,’ Meinian Onehealth, as China’s largest gateway to health demands and big data platform, possesses boundless potential for industrial expansion and influence.”“The strategic deepening of cooperation between Philips and Orange Intent Family has extended and intensified our strategic partnership with Meinian Onehealth from the previous focus on ‘early screening and precise diagnosis of high-incidence chronic diseases’ to the realm of ‘personal health management,’ helping Philips further refine its ‘full life cycle’ solution portfolio in the Chinese market.”

“Guided by the shared vision of ‘integrating healthcare services to deliver seamless care,’ the strategic partnership between Philips and Meinian Onehealth, along with the future introduction of more innovative platforms and business models such as ‘Orange Family,’ will leverage complementary strengths and form a powerful alliance. This collaboration is poised to accelerate the development of the health industry, enabling all parties to seize new market opportunities and jointly advance the realization of China’s future landscape for comprehensive health.”

Mr. Yu Rong, Chairman of Meinian Onehealth Healthcare, stated: “Philips is a global leader in health technology, focusing on four key areas: cardiovascular care, oncology, respiratory care, and maternal and child health. Today, Philips’ strategic investment in Chengyi Jiaren will become an important link in the Meinian healthcare industry ecosystem. Together, we will explore the respiratory health industry market, synergizing Philips’ professional expertise, Meinian’s precise needs, and Chengyi’s service system to achieve complementary advantages, mutual growth, and promote the sustained and healthy development of the industry.”

Philips Sleep and Respiratory Care Experience Center Unveiling Ceremony

On the day of signing,Philips and Chengyi Jiaren Unveil the First “Sleep and Breathing Experience Center”The center will closely integrate patient disease progression management with device management, providing “one-stop comprehensive chronic disease management services”—including reception, screening, trials, demonstrations, sales, education, and support—for high-risk populations and patients with sleep-disordered breathing and chronic obstructive pulmonary disease (COPD). In the future, such experience centers will be replicated across National Health Intelligence Valley locations and Meinian Onehealth Healthcare stores, gradually achieving economies of scale and leading the domestic market for chronic disease management in sleep-related respiratory disorders.

Royal Philips is a leading health technology company dedicated to improving people’s health and enabling better outcomes across the entire healthcare continuum—from healthy lifestyles and disease prevention to diagnosis, treatment, and home care.

Philips will continue to launch integrated innovative solutions by leveraging advanced technology, extensive clinical experience, and deep consumer insights. The company currently holds a leading position in the fields of diagnostic imaging, image-guided therapy, patient monitoring, health informatics, and consumer health and home care.

Headquartered in the Netherlands, Philips reported €17.4 billion in sales for its HealthTech business in 2016, employs approximately 71,000 people worldwide, and maintains sales and service operations in more than 100 countries.

Orange Family Technology (Tianjin) Co., Ltd. is a professional service provider specializing in digital solutions for telemedicine. The founding team comprises seasoned professionals from the fields of health management, mobile internet, and medical devices. The company has been granted over 40 software copyrights and patents, and is recognized as a National High-Tech Enterprise and a Tianjin High-Tech Enterprise. Over the years, it has received numerous honors, including the “Top 10 Excellent Enterprise Award” at the 4th China Innovation and Entrepreneurship Competition, the “2015 Excellent Digital Healthcare Solution Award,” and the Third Prize at the Tianjin Innovation and Entrepreneurship Competition.

After years of innovative research and development, a medical health management service system has been established, anchored by products such as the “Chengyi Pulse Oximeter” and the “Remote Portable Pulmonary Function Tester.” By pioneering China’s first cloud-based doctor-patient interaction platforms, “Chengyi Health” and “Chengyi Doctor,” and establishing a “Diagnosis and Treatment Management System for Chronic Respiratory Diseases,” we have created a comprehensive management and rehabilitation program for patients with chronic respiratory diseases, covering initial screening, treatment, and recovery.

Meinian Onehealth (SZ002044) is China’s largest health checkup and medical services group, a constituent of the CSI 300 Index, and ranks first in market capitalization among listed companies in the health service sector. It owns professional health checkup and medical brands including “Meinian Grand Health,” “Ciming,” “Ciming Aoya,” and “Meizhao.”

Currently, it operates nearly 400 medical and physical examination centers in more than 200 core cities across China, making it the world’s largest preventive medicine platform and primary entry point for health services. In 2017, Meinian Onehealth provided professional health services to nearly 20 million individuals, with projections indicating that it will serve over 100 million individuals by 2021.

Leveraging its vast customer base, a massive platform of precise health big data, and a standardized medical service network spanning across China, Meinian Onehealth is building the most promising large-scale health industry cluster in China. By serving as both an ecosystem platform and an incubation carrier, Meinian Onehealth has successfully established a highly influential core ecosystem for the health industry, while continuously striving to lead the development of preventive medicine and drive transformation in China’s health management sector.